Search PubMed⌕ Search

Biomedical subjects

W Jilg

Publications and source records attributed to W Jilg.

118 records · Page 7Linked to original sources
PubMed1983

Effect of vaccination schedule and dialysis on hepatitis B vaccination response in uraemic patients.

Antibody response to vaccination with hepatitis B vaccine (HB-Vax) was evaluated in 43 staff, 81 dialysis patients and 12 non-dialysed uraemic patients. We confirmed less frequent seroconversion and lower concentration of antibody to hepatitis B surface antigen (anti-HBs) in dialysis patients despite a higher dose (40 micrograms vaccine). However, more frequent vaccination (5 times vs 3) increased anti-HBs concentration to almost normal. Concomitant administration of hepatitis B immunoglobulin (HBIG) and hepatitis B vaccine (passive/active) did not interfere with vaccination success. Antibody response was equally poor in dialysed non-dialysed uraemic patients.

Adult↗
PubMed1981

Lymphocyte surface proteins recognized by an anti-thymocyte-globulin.

Rat lymphocyte surface proteins were labelled by lactoperoxidase-catalysed iodination and immunoprecipitated by an anti-thymocyte globulin (ATG). ATG-Reactive proteins from cortical and medullary thymocytes, peripheral T cells and B cells were examined by gel electrophoresis. Several surface molecules were identified which showed differences in their distribution in the four cell populations. A 105 000-Da component was found in relatively high density on thymocytes and peripheral T cells only. Two high-molecular mass components of 205 000 Da and 190 000 Da were observed which were highly specific for peripheral T cells. These molecules appeared to share antigenic determinants with two other proteins found on the surface of both peripheral T cells and thymocytes. Limited proteolysis with Staphylococcus aureus protease showed these four proteins to have a similar peptide composition indicating the existence of a family of related surface molecules with varying expression on different cells. One of these T cell-specific proteins (P 190) was present at a comparatively high density, making up about 4% of the membrane protein. The main protein recognised by ATG was a component with a molecular mass of 175 000 Da found on all lymphocytes which made up about 7% of membrane protein. The other ATG-reactive proteins were all minor components of the cell surface, constituting less than 1% of membrane protein.

Animals↗
PubMed1980

Radio-iodinated surface proteins of electrophoretically separated rat lymphocytes.

Rat thymocytes and lymph node cells were separated into three T and one B subpopulation by means of free flow electrophoresis. The surface proteins of the separated cells were labeled by lactoperoxidase catalysed radioiodination. Most of the label was demonstrated to be at the cell surface. The labelled cells were either lysed in sodium dodecyl sulphate or treated with Nonidet P-40 to extract cell proteins. The radioiodinated proteins were analysed on sodium dodecyl sulphate polyacrylamide gel electrophoresis followed by autoradiography. In contrast to sodium dodecyl sulphate Nonidet P-40 did not extract cell proteins completely. Furthermore the degree of extraction varied considerably in the different cell populations. 58% of protein bound radioactivity was extracted from thymocytes, 67% from peripheral T cells and 81% from B cells. Gel electrophoresis revealed that four proteins were not extracted at all, whereas five components were better soluble in Nonidet P-40 than all other proteins. One protein was extracted from B cells only although it was present in all cells. Although the surface protein patterns of the four lymphocyte subpopulations were rather similar, distinctive differences could be found. B cells had six labelled proteins which seemed to be absent in the other cells, In the T cell group, three protein bands were identified, each with specificity for peripheral T cells, thymocytes and all T cells respectively. Four other proteins were found which showed quantitative differences between the four cell groups.

Animals↗
PubMedDate not supplied

Four-year experience with a recombinant hepatitis B vaccine.

Three hundred and forty-three healthy adults were vaccinated with five different lots of recombinant hepatitis B vaccine. Three hundred and forty (99.1%) individuals produced antibodies against hepatitis B surface antigen (anti-HBs). Peak anti-HBs concentrations were significantly higher in females and younger individuals. All anti-HBs positive individuals developed antibodies to the common determinant "a" of HBsAg. The vaccine was well tolerated, without severe side reactions. Persistence of anti-HBs was followed in 130 individuals for 3, and in 15 for 4 years after the first vaccination of these two groups. 21.7% and 32.3%, respectively, no longer had protective levels of anti-HBs after this time. The persistence of anti-HBs was dependent on peak anti-HBs levels, with consistent kinetics of anti-HBs decline. Revaccination of individuals whose specific antibody levels had fallen below 10 IU/l led to a prompt anti-HBs response. Comparison with individuals vaccinated with plasma-derived hepatitis B vaccine revealed no substantial differences between the two vaccines.

Adolescent↗